Posters

Results of corneal collagen cross-linking in adolescents with progressive keratoconus

Poster Details

First Author: R.Gaster USA

Co Author(s):    J. Zikry   A. Canedo   Y. Rabinowitz              

Abstract Details

Purpose:

To determine the safety and efficacy of epithelium-off corneal collagen cross-linking (CXL) in adolescent patients with progressive keratoconus.

Setting:

This is a retrospective clinical trial of CXL in adolescent patients with progressive keratoconus seen at the Cornea Eye Institute,Beverly Hills, California.

Methods:

Of 100 eyes of adolescent patients with progressive keratoconus between 10-19 years old who underwent CXL,77 eyes were evaluated at 6 months and 57 eyes were evaluated at one-year post-CXL. Uncorrected visual acuity (UCVA),best corrected visual acuity (BCVA), topographic maximum keratometry (Kmax),minimum pachymetry, and refractive spherical equivalent (SE) were measured preoperatively and 6 and 12 months postoperatively. P values less than 0.05 were considered statistically significant.

Results:

LogMAR UCVA significantly improved from 0.71 pre-op to 0.62 and 0.59 at 6 and 12 months postop respectively (p=0.01).LogMAR BCVA significantly improved from 0.30 pre-op to 0.25 and 0.23 at 6 and 12 months post-op (p=0.02). Kmax significantly decreased from 51.7D pre-op to 50.3D and 50.0D at 6 and 12 months post-op respectively (p=0.0001). Minimum pachymetry significantly decreased from 456 microns pre-op to 436 and 433 microns at 6 and 12 months postop respectively (p=0.0001). SE significantly improved from -3.32D pre-op to -2.04D and -2.35D at 6 and 12 months postop respectively (p=0.0001).

Conclusions:

CXL in patients aged 10 to 19 years is safe and efficacious, halts progression of keratoconus, and can improve UCVA, BCVA, Kmax and SE with few complications. Minimum pachymetry decreases and stabilizes from 6 to 12 months post-CXL. Ophthalmologists should encourage young patients with progressive keratoconus to consider prompt evaluation and CXL when appropriate.

Financial Disclosure:

NONE